Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
162.22B
Market cap162.22B
Price-Earnings ratio
41.28
Price-Earnings ratio41.28
Dividend yield
5.96%
Dividend yield5.96%
Average volume
38.21M
Average volume38.21M
High today
$28.75
High today$28.75
Low today
$28.30
Low today$28.30
Open price
$28.48
Open price$28.48
Volume
35.35M
Volume35.35M
52 Week high
$31.44
52 Week high$31.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $28.30. The company's market cap stands at 162.22B, with a P/E ratio of 41.28 and a dividend yield of 5.96%.

On 2026-11-18, Pfizer(PFE) stock moved within a range of $28.30 to $28.75. With shares now at $28.30, the stock is trading 0.0% above its intraday low and -1.6% below the session's peak.

Trading activity shows a volume of 35.35M, compared to an average daily volume of 38.21M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

PFE News

Simply Wall St 6h
What Is Pfizer Asking Of Its $10 Billion Metsera Bet?

Pfizer (NYSE:PFE) agreed to acquire obesity drug developer Metsera for about US$10b in cash, expanding its metabolic disease portfolio. The deal strengthens Pf...

What Is Pfizer Asking Of Its $10 Billion Metsera Bet?
24/7 Wall St. 10h
Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%
The Motley Fool 11h
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue

Johnson & Johnson: Steady Upward Recent Revenue Growth Johnson & Johnson (JNJ -0.97%) primarily generates revenue by developing and selling pharmaceutical and m...

Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue

Analyst ratings

63%

of 27 ratings
Buy
25.9%
Hold
63%
Sell
11.1%

More PFE News

TipRanks 13h
Pfizer Updates Real-World Safety Study of Xeljanz XR

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer’s study, officially titled “KOREAN POST-MARKETING SURVEILLANCE FOR...

Investing.com 19h
Pfizer at jefferies global healthcare conference: pipeline, ai and loe - Investing.com

...

Pfizer at jefferies global healthcare conference: pipeline, ai and loe - Investing.com
Simply Wall St 2d
Is Pfizer Undervalued On Its $1.5b Berobenatide Funding Deal?

Pfizer (PFE) just secured up to US$1.5b in external funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP 1 obesity drug, whil...

Is Pfizer Undervalued On Its $1.5b Berobenatide Funding Deal?
The Motley Fool 4d
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

As the global health landscape shifts toward obesity treatments, investors are weighing the rapid growth of Novo Nordisk A/S (NVO +2.41%) against the deep-roote...

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
The Motley Fool 4d
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

Pfizer (PFE +0.21%) and AbbVie (ABBV +0.20%) rank among the biggest drugmakers in the world. Both pharma stocks have also been favorites for many income investo...

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Simply Wall St 4d
Pfizer Stock Looks Above Fair Value As Shares Rebound

has climbed back this year after a difficult five year stretch, which raises a simple question for anyone looking at the ticker today. Is the current share pric...

Pfizer Stock Looks Above Fair Value As Shares Rebound
The Motley Fool 4d
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?

Pfizer (PFE +0.00%) has a huge 5.8% dividend yield. That compares to roughly 1% for the broader market and 1.3% for the average pharmaceutical stock. Pfizer's s...

Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.